SIC
NVO

Samalin Investment Counsel’s Novo Nordisk NVO Stock Holding History

Samalin Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$830K Buy
17,321
+7,315
+73% +$314K 0.26% 93
2026
Q1 		$368K Sell
10,006
-1,317
-12% -$62.4K 0.13% 214
2025
Q4 		$576K Buy
11,323
+616
+6% +$31.5K 0.2% 150
2025
Q3 		$594K Buy
10,707
+3,728
+53% +$218K 0.2% 146
2025
Q2 		$482K Buy
6,979
+372
+6% +$25.3K 0.18% 177
2025
Q1 		$459K Sell
6,607
-452
-6% -$37.3K 0.19% 170
2024
Q4 		$607K Sell
7,059
-470
-6% -$50.8K 0.26% 109
2024
Q3 		$896K Sell
7,529
-475
-6% -$63.3K 0.39% 65
2024
Q2 		$1.14M Buy
8,004
+7
+0.1% +$928 0.53% 45
2024
Q1 		$1.03M Buy
7,997
+126
+2% +$15K 0.49% 53
2023
Q4 		$814K Sell
7,871
-241
-3% -$23.8K 0.41% 68
2023
Q3 		$738K Sell
8,112
-84
-1% -$7.4K 0.42% 69
2023
Q2 		$663K Sell
8,196
-2
-0% -$163 0.36% 74
2023
Q1 		$652K Buy
8,198
+36
+0.4% +$2.55K 0.39% 71
2022
Q4 		$552K Sell
8,162
-396
-5% -$23.2K 0.35% 86
2022
Q3 		$426K Sell
8,558
-158
-2% -$8.46K 0.31% 96
2022
Q2 		$486K Buy
8,716
+102
+1% +$5.66K 0.34% 84
2022
Q1 		$478K Hold
8,614
– – 0.29% 102
2021
Q4 		$482K Sell
8,614
-30
-0.3% -$1.63K 0.29% 100
2021
Q3 		$415K Buy
8,644
+312
+4% +$15.1K 0.27% 119
2021
Q2 		$349K Sell
8,332
-94
-1% -$3.64K 0.23% 158
2021
Q1 		$284K Sell
8,426
-44
-0.5% -$1.57K 0.19% 176
2020
Q4 		$296K Sell
8,470
-194
-2% -$6.71K 0.22% 157
2020
Q3 		$301K Buy
8,664
+236
+3% +$7.87K 0.27% 121
2020
Q2 		$275K Sell
8,428
-8,388
-50% -$268K 0.29% 114
2020
Q1 		$506K Sell
16,816
-100
-0.6% -$2.98K 0.68% 43
2019
Q4 		$489K Buy
+16,916
New +$468K 0.41% 63

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Samalin Investment Counsel's NVO Position: Q2 2026 in Review

Samalin Investment Counsel increased its Novo Nordisk (NVO) stake by 73% in Q2 2026, buying an estimated $314K and bringing the position to 17,321 shares worth $830K. The position accounts for 0.26% of the portfolio, ranked #93.

Samalin Investment Counsel first reported a position in NVO in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.14M in Q2 2024. 516 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Samalin Investment Counsel held 17,321 shares of Novo Nordisk worth $830K as of Q2 2026.
  • Samalin Investment Counsel bought 7,315 Novo Nordisk shares in Q2 2026, an estimated $314K.
  • Novo Nordisk made up 0.26% of Samalin Investment Counsel's portfolio in Q2 2026, its #93 holding.
  • Samalin Investment Counsel first reported a position in Novo Nordisk in Q4 2019 and has held it in 27 quarters since.
  • Samalin Investment Counsel's Novo Nordisk position peaked at $1.14M in Q2 2024.
  • 516 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.